TransMedics Group (NASDAQ:TMDX) Earns “Outperform” Rating from Oppenheimer

TransMedics Group (NASDAQ:TMDX)‘s stock had its “outperform” rating reiterated by investment analysts at Oppenheimer in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $125.00 price target on the stock. Oppenheimer’s price objective points to a potential upside of 61.37% from the company’s previous close.

A number of other analysts have also weighed in on the company. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Tuesday. Canaccord Genuity Group reduced their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. TD Cowen lowered their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Piper Sandler cut their price target on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Finally, Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Trading Down 9.0 %

Shares of NASDAQ:TMDX traded down $7.68 during trading on Tuesday, reaching $77.46. The company’s stock had a trading volume of 592,770 shares, compared to its average volume of 999,196. The stock has a market capitalization of $2.60 billion, a PE ratio of 82.41 and a beta of 2.06. TransMedics Group has a 12 month low of $68.84 and a 12 month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm’s 50 day simple moving average is $110.21 and its two-hundred day simple moving average is $135.81.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.12) EPS. On average, research analysts predict that TransMedics Group will post 1.01 EPS for the current fiscal year.

Insider Activity

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,180,642.53. This trade represents a 12.27 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This trade represents a 12.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,958 shares of company stock worth $3,470,328. 7.00% of the stock is currently owned by corporate insiders.

Institutional Trading of TransMedics Group

A number of institutional investors and hedge funds have recently bought and sold shares of TMDX. State of Alaska Department of Revenue acquired a new position in shares of TransMedics Group during the third quarter worth $2,560,000. Vaughan Nelson Investment Management L.P. boosted its position in TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after buying an additional 64,360 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of TransMedics Group by 665.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after acquiring an additional 64,872 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of TransMedics Group by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after acquiring an additional 6,634 shares during the last quarter. Finally, Thrivent Financial for Lutherans acquired a new position in shares of TransMedics Group in the third quarter worth about $4,113,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.